Dagrocorat

Dagrocorat (developmental code names PF-00251802, PF-251802) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.^[1][2][3][4] It is described as a partial agonist and "dissociable" agonist of the glucocorticoid receptor.^[5][6] The drug reached phase I clinical trials prior to the discontinuation of its development.^[1][3][4] The C2α dihydrogen phosphate ester of dagrocorat, fosdagrocorat, was also under investigation, but its development was terminated as well.^[7]

Dagrocorat

Clinical data
Other names	PF-00251802; PF-251802
Drug class	Selective glucocorticoid receptor modulator
Identifiers
IUPAC name (4bS,7R,8aR)-4b-Benzyl-7-hydroxy-N-(2-methylpyridin-3-yl)-7-(trifluoromethyl)-5,6,8,8a,9,10-hexahydrophenanthrene-2-carboxamide
CAS Number	1044535-52-5
PubChem CID	24873449
ChemSpider	32700623
UNII	OPM23UN90U
KEGG	D10617
ChEMBL	ChEMBL3137304
CompTox Dashboard (EPA)	DTXSID60146493
Chemical and physical data
Formula	C29H29F3N2O2
Molar mass	494.558 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC=N1)NC(=O)C2=CC3=C(C=C2)[C@@]4(CC[C@@](C[C@H]4CC3)(C(F)(F)F)O)CC5=CC=CC=C5
InChI InChI=1S/C29H29F3N2O2/c1-19-25(8-5-15-33-19)34-26(35)22-10-12-24-21(16-22)9-11-23-18-28(36,29(30,31)32)14-13-27(23,24)17-20-6-3-2-4-7-20/h2-8,10,12,15-16,23,36H,9,11,13-14,17-18H2,1H3,(H,34,35)/t23-,27+,28-/m1/s1 Key:QJJBNCHSWFGXML-KEKPKEOLSA-N

See also

• AZD-5423
• Mapracorat
• Fosdagrocorat